research Provenge is Talk of GU Malignancies Congress
Provenge extends prostate cancer survival by about 4 months.
Search
forResearch
3 / 1000+ results
research Management of Advanced Prostate Cancer Undergoing Major Shift
New treatments are making advanced prostate cancer management more complex but also more hopeful.
research NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.
Learn
1 / 801 resultslearn Valproic acid
an anticonvulsant repurposed for hair loss via histone inhibition
Community Join
— no results
Experts
— no results
Clinics
— no results